Enanta Pharmaceuticals, Inc

ENTA Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
ENTA Income Statement
ENTA Balance Sheet
ENTA Cash Flow
Congress Trading

Recent trades of ENTA by members of U.S. Congress

Politician Type Traded
Daniel S. Goldman House / D Sale $1,001 - $15,000 Jul. 12, 2023
Thomas MacArthur House / R Sale $1,001 - $15,000 May. 27, 2015
Thomas MacArthur House / R Purchase $1,001 - $15,000 Mar. 20, 2015
ENTA Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
ENTA Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
ENTA Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by ENTA's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $20,000 Nov 14, 2023 Issue: Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Spiropyrrolidine derived antiviral agents Nov. 19, 2024
  • Patent Title: Heterocyclic antiviral agents Nov. 19, 2024
  • Patent Title: Hepatitis b antiviral agents Aug. 06, 2024
  • Patent Title: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Jun. 25, 2024
  • Patent Title: Hepatitis b antiviral agents Jun. 18, 2024
  • Patent Title: Antiviral heterocyclic compounds Jun. 11, 2024
  • Patent Title: Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid Jun. 11, 2024
  • Patent Title: Saturated spirocyclics as antiviral agents May. 28, 2024
  • Patent Title: Spiropyrrolidine derived antiviral agents May. 07, 2024
  • Patent Title: Macrocyclic antiviral agents Apr. 30, 2024
  • Patent Title: Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof Apr. 16, 2024
  • Patent Title: Benzodiazepine derivatives as rsv inhibitors Apr. 09, 2024
  • Patent Title: Antiviral heterocyclic compounds Apr. 02, 2024
  • Patent Title: Heterocyclic compounds as anti-viral agents Apr. 02, 2024
  • Patent Title: Spiropyrrolidine derived antiviral agents Mar. 05, 2024
  • Patent Title: Spiropyrrolidine derived antiviral agents Feb. 27, 2024
  • Patent Title: Benzodiazepine derivatives as rsv inhibitors Feb. 27, 2024
  • Patent Title: Functionalized heterocycles as antiviral agents Feb. 06, 2024
  • Patent Title: Alkyne-containing antiviral agents Jan. 02, 2024
  • Patent Title: Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Dec. 05, 2023
  • Patent Title: Hepatitis b antiviral agents Sep. 19, 2023
  • Patent Title: Substituted heterocycles as antiviral agents Aug. 29, 2023
  • Patent Title: Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof Aug. 08, 2023
  • Patent Title: Hepatitis b antiviral agents Mar. 07, 2023
  • Patent Title: Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof Feb. 14, 2023
  • Patent Title: Antiviral heterocyclic compounds Feb. 07, 2023
  • Patent Title: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Jan. 24, 2023
  • Patent Title: Isoxazole derivatives as fxr agonists and methods of use thereof Jan. 17, 2023
  • Patent Title: Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors Dec. 27, 2022
  • Patent Title: Antiviral heterocyclic compounds Nov. 22, 2022
  • Patent Title: Substituted pyrrolo[1,2-c]pyrimidines as hepatitis b antiviral agents Oct. 18, 2022
  • Patent Title: Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors Oct. 11, 2022
  • Patent Title: Heterocyclic compounds as anti-viral agents Aug. 23, 2022
  • Patent Title: Benzodiazepine derivatives as rsv inhibitors Jul. 19, 2022
  • Patent Title: Spiropyrrolidine derived antiviral agents Jul. 12, 2022
  • Patent Title: Functionalized heterocycles as antiviral agents Jul. 05, 2022
  • Patent Title: Functionalized peptides as antiviral agents Jun. 14, 2022
  • Patent Title: Spiropyrrolidine derived antiviral agents Jun. 07, 2022
  • Patent Title: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof May. 31, 2022
  • Patent Title: Spiropyrrolidine derived antiviral agents May. 24, 2022
  • Patent Title: Spiropyrrolidine derived antiviral agents May. 10, 2022
  • Patent Title: Macrocyclic spiropyrrolidine derived antiviral agents May. 03, 2022
  • Patent Title: Benzodiazepine derivatives as rsv inhibitors Feb. 22, 2022
  • Patent Title: Hepatitis b antiviral agents Feb. 01, 2022
  • Patent Title: Functionalized heterocycles as antiviral agents Feb. 01, 2022
  • Patent Title: Functionalized heterocycles as antiviral agents Dec. 14, 2021
  • Patent Title: Heterocyclic compounds as rsv inhibitors Nov. 23, 2021
  • Patent Title: Heterocyclic compounds as rsv inhibitors Aug. 17, 2021
  • Patent Title: Substituted heterocycles as antiviral agents Jul. 13, 2021
  • Patent Title: Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof Jun. 22, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of ENTA in WallStreetBets Daily Discussion

ENTA News

Recent insights relating to ENTA

CNBC Recommendations

Recent picks made for ENTA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ENTA

ENTA Top Shareholders
Shareholder
Shares Held
ENTA Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

ENTA Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view ENTA Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top